Depo-Provera litigation · Evidence guide
The Depo-Provera cases focus on meningioma risk and warning history
Federal cases allege that repeated injectable medroxyprogesterone use contributed to meningiomas. FDA added risk information in 2025, while observational research cannot decide individual causation.
What plaintiffs allege
The federal lawsuits allege that injectable depot medroxyprogesterone acetate caused some users to develop meningiomas and that warnings were inadequate. The JPML created MDL 3140 to coordinate shared pretrial questions; it did not decide whether those allegations are true.
The cases are pending in the Northern District of Florida before Judge M. Casey Rodgers. JPML listed 6,294 actions pending on August 3, 2026.
What changed on the label
In 2025, FDA approved additions about meningioma risk to Depo-Provera prescribing and patient information. That is current regulatory evidence, but it does not decide whether earlier warnings were legally adequate or whether the medicine caused an individual tumor.
What the research can show
A 2024 French national case-control study reported an association between prolonged injectable medroxyprogesterone acetate use and surgery for intracranial meningioma. The number of exposed cases was small, and the observational design can identify an association without proving causation for one person.
Verification ledger
Primary sources
Depo-Provera transfer order
The official allegation and centralization record.
MDL 3140, Document 120
Depo-Provera supplement approval
FDA's 2025 approval of meningioma-related label information.
Reference ID 5710882
Progestogens and intracranial meningioma
The original national case-control study.
PMID 38537944 · DOI 10.1136/bmj-2023-078078
Pending MDLs
The dated federal docket snapshot.
Page 1, MDL 3140